
Insmed surged ~21% Thursday to close at $144.46 after Bloomberg reported Sanofi is working with advisers on a possible acquisition of the respiratory drugmaker, in what could be the largest biopharma deal since Pfizer's $43B Seagen buyout. No offer price has been reported, neither company is commenting, and a decision could be weeks away, but Insmed's Brinsupri alone did $400M in Q3 revenue, up from $28M a year ago.